Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation:Effects on virus replication and recurrent hepatitis

瞄准：决定 calcineurin 禁止者， cyclosporine 和 tacrolimus 的效果，在丙肝上，在病人的周期性的丙肝的病毒(HCV ) 复制和活动张贴肝移植。方法：在我们的中心为在 1999 和 2003 之间的联系 HCV 的肝肝硬化收到了肝移植的 107 个病人的一个队的数据回顾地被分析。浆液 HCV-RNA 的水平和周期性的肝炎的活动在作为主要抑制免疫力的代理人和没在移植以后在开始的 12 瞬间以内导致胆汁的复杂并发症的不那样类似的抑制免疫力的政体收到了 cyclosporine 或 tacrolimus 的 47 个病人之间被比较。结果：HCV-RNA 在移植以后在 3 瞬间以内增加了，但是 cyclosporine 组和 tacrolimus 组之间的差别是不足道的(在 12 瞬间的 P=0.49 ) 。另外，由浆液 transaminases 决定了的周期性的肝炎并且门发炎和纤维变性的组织学的分级没在 12 瞬间(P=0.34 ) 以后显示出有效差量。结论：一个主要抑制免疫力的代理人不在肝移植以后在感染 HCV 的病人影响周期性的肝炎的正式就职或严厉的 Cyclosporine 或 tacrolimus。

AIM： To determine the effects of the calcineurin inhibitors, cyclosporine and tacrolimus, on hepatitis C virus （HCV） replication and activity of recurrent hepatitis C in patients post liver transplantation. METHODS： The data of a cohort of 107 patients who received liver transplantation for HCV-associated liver cirrhosis between 1999 and 2003 in our center were retrospectively analyzed. The level of serum HCV-RNA and the activity of recurrent hepatitis were compared between 47 patients who received either cyclosporine or tacrolimus as the primary immunosuppressive agent and an otherwise similar immunosuppressive regimen which did not lead to biliary complications within the first 12 mo after transplantation. RESULTS： HCV-RNA increased within 3 mo after transplantation but the differences between the cyclosporine group and the tacrolimus group were insignificant （P=0.49 at 12 too）. In addition, recurrent hepatitis as determined by serum transarninases and histological grading of portal inflammation and fibrosis showed no significant difference after 12 mo （P= 0.34）. CONCLUSION： Cyclosporine or tacrolimus as a primary immunosuppressive agent does not influence the induction or severity of recurrent hepatitis in HCV- infected patients after liver transplantation.